UK BIOTECH SUMMIT 2019

October 8, 2019, Royal College of Physicians, London

event instructions
Silicon Valley Bank Endpoints News Instinctif Partners
Contact Mike Peck ( mike@endpointsnews.com) for sponsorship opportunities.

An exclusive opportunity to learn from and network with the top newsmakers in UK biotech.

Endpoints' half-day summit on October 8 will feature a prominent group of the top executives leading a new generation of UK biotechs in an industry that has undergone major changes in recent years — with more on the way.

We’ll take a look at the evolving design of cancer drug trials, discussing prospective changes that the Parker Institute for Cancer Immunotherapy and others are calling for; ways in which oncology studies will be adapted in the next couple of years and the influence that will have on developers in general, regardless of disease.

There will also be a panel discussion on UK biotech financial issues in a post-Brexit world — after serious turmoil at a high-profile life sciences investment fund — and regulatory trends that influence the availability of capital. To kick this off Endpoints News will be running a special poll of UK readers in advance of the summit to take the pulse of the biopharma, examining how fundraising has changed, the dominance of a particular public market and the impact new investors from China have had.

Our event will feature a one-on-one fireside chat, an exchange with the audience, with regular opportunities for networking, capped by a mixer with wine, beer and snacks.

UKBIO19 PANELISTS

Hal Barron

    fireside chat

John Dawson

    Cancer trials panelist

Mohammed Dar

    Cancer trials panelist

Malte Peters

    Cancer trials panelist

Peter Johnson

    Cancer trials panelist

Christian Itin

    Cancer trials panelist

Denise Scots-Knight

    Finance Panelist

Martin Murphy

    Finance Panelist

Sascha Bucher

    Finance Panelist

Arie Belldegrun

    Finance panelist

Nooman Haque

    Moderator: finance

John Carroll

    Moderator: CANCER trials

Sign up to receive updates as they become available